HOUSE DOCKET, NO. 2163        FILED ON: 1/17/2019

HOUSE  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  No. 1016

 

The Commonwealth of Massachusetts

_________________

PRESENTED BY:

Bradley H. Jones, Jr.

_________________

To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General
Court assembled:

The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying bill:

An Act establishing a commission to study maximum allowable costs lists.

_______________

PETITION OF:

 

Name:

District/Address:

Bradley H. Jones, Jr.

20th Middlesex

Bradford Hill

4th Essex

Elizabeth A. Poirier

14th Bristol

Susan Williams Gifford

2nd Plymouth

Paul K. Frost

7th Worcester

Todd M. Smola

1st Hampden

Randy Hunt

5th Barnstable

Angelo L. D'Emilia

8th Plymouth

Steven S. Howitt

4th Bristol

Michael J. Soter

8th Worcester

Hannah Kane

11th Worcester

Bruce E. Tarr

First Essex and Middlesex


HOUSE DOCKET, NO. 2163        FILED ON: 1/17/2019

HOUSE  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  No. 1016

By Mr. Jones of North Reading, a petition (accompanied by bill, House, No. 1016) of Bradley H. Jones, Jr., and others for an investigation by a special commission (including members of the General Court) relative to maximum allowable costs lists utilized by payers and pharmaceutical benefit managers to identify the maximum amount health plans will pay for certain prescription drugs.  Financial Services.

 

The Commonwealth of Massachusetts

 

_______________

In the One Hundred and Ninety-First General Court
(2019-2020)

_______________

 

An Act establishing a commission to study maximum allowable costs lists.

 

Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority of the same, as follows:
 

SECTION 1. Notwithstanding any general or special law to the contrary, there shall be a special commission established to investigate the use of maximum allowable costs lists, utilized by payers and pharmaceutical benefit managers to identify the maximum amount that a plan will pay for various prescription drugs. The commission’s review shall include, but not be limited to, current practices surrounding the determination and use of maximum allowable costs lists and their financial implications; industry-wide standardization for the development and use of maximum allowable costs lists; and transparency into the processes of developing and utilizing maximum allowable costs lists.

The commission shall consist of 10 members: the secretary of health and human services, or a designee; the speaker of the house of representatives, or a designee; the senate president, or a designee; the minority leader of the house of representatives, or a designee; the minority leader of the senate, or a designee; a representative from the Massachusetts Association of Health Plans; a representative from the Massachusetts Pharmacists Association; one person who shall be an advocate for health care providers, to be appointed by the governor; one person who shall be an advocate for pharmaceutical companies, to be appointed by the governor; and one person who shall be an advocate for pharmaceutical benefit managers, to be appointed by the governor.

The commission shall submit its report and findings, along with any draft of legislation, to the house and senate committees on ways and means, the joint committee on health care financing, and the clerks of the house of representatives and the senate within 180 days of the passage of this act.